Davide Rossi

Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Haematologica, 22 febbraio 2024

2) PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

bioRxiv, 16 novembre 2023

3) ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells

British Journal of Haematology, 16 agosto 2023

4) Marginal zone lymphomas

Hematological Oncology, giugno 2023

5) Acquired haemophilia A in southern Switzerland from 2013 to 2019: a case series

Swiss Medical Weekly, 31 marzo 2023

6) The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA

Hematological Oncology, febbraio 2020

7) Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia

Hematological Oncology, dicembre 2022

8) KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Haematologica, giugno 2020

9) ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

bioRxiv, 2 gennaio 2023

10) In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103

British Journal of Haematology, 9 dicembre 2022

11) HTGQC and shinyHTGQC: an R package and shinyR application for quality controls of HTG EDGE-seq protocols

GIGAbyte, 2 dicembre 2022

12) Bacterial infection-driven lymphomagenesis

Current Opinion in Oncology, 1 settembre 2022

13) SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma

Blood Advances, 12 luglio 2022

17) Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

Blood Advances, 23 novembre 2021

18) Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma

British Journal of Haematology, 22 luglio 2021

19) Epigenetic Trajectories of the Premalignant-to-Malignant Transition of Chronic Lymphocytic Leukemia

Blood Cancer Discovery, gennaio 2021

20) Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

Leukemia, 24 giugno 2021

21) Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma

Proceedings of the National Academy of Sciences of the United States of America, 1 giugno 2021

22) Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us

Trends in Cancer, 21 maggio 2021

23) TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases

American Journal of Hematology, 14 maggio 2021

24) Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology, 28 aprile 2021

25) Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine ...

American Journal of Hematology, 20 aprile 2021

26) Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study

American Journal of Hematology, 13 febbraio 2021

27) Richter Syndrome

Current Oncology Reports, 12 febbraio 2021

28) Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1

Blood, 4 febbraio 2021

29) Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance

Journal of the National Comprehensive Cancer Network (JNCCN), 31 dicembre 2020

30) Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

European Journal of Haematology, 30 dicembre 2020

31) Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Haematologica, 1 novembre 2020

32) Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis

Journal of Thrombosis and Thrombolysis, https://link.springer.com/article/10.1007%2Fs11239-020-02244-y

33) Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type

Cancers, 15 luglio 2020

34) International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Blood, 21 maggio 2020

35) Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.

American Society of Hematology, https://ashpublications.org/bloodadvances/article/4/5/819/452604/Copanlisib-synergizes-with-conventional-and

36) Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

Haematologica, 31 gennaio 2020

Davide Rossi
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona

Davide Rossi
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Experimental Hematology
as Group Leader [Rif. 55110]

Davide Rossi has coordinated or participated in the 36 publications here listed (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations)